Taurolidine is an antibacterial and antifungal agent with a mechanism of action that is less prone to development of antimicrobial resistance. A taurolidine/heparin lock solution carries a lower risk ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA approved a taurolidine and heparin (DefenCath) catheter lock solution for reducing the risk of bloodstream infections in patients on dialysis. Approved under a special limited agency pathway, ...

This is the first FDA-approved antimicrobial catheter lock solution. The FDA has approved taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections ...

BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 26, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the ...

The alternative text for this image may have been generated using AI. Taurolidine was kindly provided by Carter Wallace Inc (Cranbury, NJ, USA) as a 2% solution in 5% Kollidon 17PF. RPMI 1640, ...

The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...

BERKELEY HEIGHTS, N.J., July 08, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the ...

Please provide your email address to receive an email when new articles are posted on . The approval comes after results of the phase 3 LOCK-IT-100 clinical trial. DefenCath reduced the risk of ...

BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...